MingMed seeks Hong Kong listing to fund research and launch Botox alternative
The drug developer, based in the Nansha district of Guangzhou, said it would set up an incubation centre in
the Hong Kong Science and Technology Park in the third quarter.
'Hong Kong has many good universities and research institutes, but it [does not have] a lot of innovative biotech firms,' said MingMed CEO Zhang Yan in an interview on Friday. 'We aim to [turn] early-stage research discoveries at the city's universities into commercial products.'
He said
Hong Kong was a good platform for fundraising , early-stage drug research and global commercialisation, while Nansha was an ideal location for research and manufacturing.
MingMed has raised 1.75 billion yuan (US$243.7 million) from multiple private fundraisings, Zhang said, adding that its largest institutional investor was Beijing-based Gaorong Ventures. The company filed a Hong Kong listing application in 2022, but let it lapse due to unfavourable global market conditions for biotech stocks, he said.
Last year, MingMed completed a late-stage, phase-three clinical trial on a genetically manipulated alternative to Botox, which is used to reduce wrinkles. Botox is made from a naturally occurring botulinum toxin, a protein produced by a bacterium. Genetically engineered products could lower production costs and enhance product safety, Zhang said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
8 minutes ago
- South China Morning Post
Leapmotor's stock and sales soar to become a new challenger in China's booming EV market
Zhejiang Leapmotor Technology, once a fringe player in China's electric vehicle (EV) industry, is beating all its start-up rivals by sales and stock gains this year and analysts say there is more to come. The carmaker's Hong Kong-listed shares have doubled since January – outpacing better-known peers XPeng and Xiaomi – and have surged more than 200 per cent from a low in August last year. The company has increased its 2025 sales target to 500,000 units, up from around 290,000 a year earlier, and is tipped to deliver its first annual profit. Ten-year-old Leapmotor has won over investors by outcompeting its peers in price, principally by producing a large proportion of components in-house. A big driver behind that is the electronics and software background of co-founder Zhu Jiangming, who has helped drive the company's R&D efforts. Leapmotor co-founder Jiangming has helped drive the company's R&D efforts. Photo: Reuters 'Leapmotor's price competitiveness is remarkable, they're offering large vehicles at mass-market prices, thanks to roughly 70 per cent vertical integration,' said Xiao Feng, co-head of China industrial research at CLSA Hong Kong. 'We see strong upside potential driven by a robust product cycle and exceptional capital efficiency.' The company's shares rose 1.7 per cent on Monday to HK$66.35, up from last year's low of HK$19.54 set in August. They are projected to climb to HK$74.89 in the next 12 months, based on a Bloomberg survey of analysts. Leapmotor was established in Hangzhou in 2015 by Zhu and co-founder Fu Liquan, who together had previously set up security-camera manufacturer Dahua Technology. The carmaker remained an underdog in its early years with sales volumes trailing far behind those of industry giant BYD and also earlier start-ups such as Xpeng and Li Auto. A key to Leapmotor's catchup since then has been Zhu's insistence that the company develop as many of its own electrical components as possible to keep costs down. That focus has seen the brand being described as a 'more affordable Li Auto', referring to the latter's mid-range and premium SUVs. By way of comparison, Leapmotor's family-oriented C11 SUV released in late 2020, retails for as little as 148,800 yuan (US$20,700). Li Auto's cheapest vehicle, the L6 SUV, starts at 249,800 yuan.
South China Morning Post
11 hours ago
- South China Morning Post
Hong Kong CEOs get crash course in AI to pass on skills to 5,000 students
More than a dozen CEOs and top-level executives in Hong Kong are taking a crash course in AI with the help of a non-profit to equip them with the skills to help 5,000 secondary school students learn the essentials of the technology. The CEO training on Sunday was a key component of the AI-5000 Initiative, a collaborative effort between Project Melo and Preface, a Hong Kong-based education technology company. The project garnered support from 17 top-level executives and leaders, including M+ museum chairman Bernard Chan, Link Reit CEO George Hongchoy, and Randy Lai, the CEO of McDonald's Hong Kong. 'We believe that Hong Kong secondary students absolutely have to focus on AI,' said Kenny Lam Kwok-fung, a co-founder of Project Melo, a local non-profit focused on empowering young people that is co-running the programme. Being held between September this year and March 2026, more than 50 schools are taking part in the programme. The courses will be delivered by Preface staff, students from Project Melo and the 15 participating CEOs. The training programme is being launched amid a wider push by the government to get young people interested in the technology.
South China Morning Post
14 hours ago
- South China Morning Post
1 in 3 eczema patients in Hong Kong face workplace hostility: poll
One in three eczema patients in Hong Kong experienced workplace hostility, including exclusion or mockery by colleagues due to their condition, a survey by the Medical and Health Advancement Federation has found. The survey released on Sunday aimed to raise awareness of the physical and mental challenges faced by eczema patients, who accounted for 20 per cent of the population. The federation conducted the survey between June and July this year, interviewing 240 people who were employed and had sought treatment for the condition in the past five years. Eczema is a condition that causes dry and itchy patches of skin. Some reported discriminatory treatment at work, with 32.5 per cent saying they were excluded or mocked by colleagues or supervisors due to their condition. One-fifth of them said they were rejected for a job due to the condition. An equal number felt that the condition hindered their promotion opportunities. More than 70 per cent of respondents said they experienced a decline in productivity and work performance due to insufficient rest caused by eczema. About 40 per cent said they had to take time off work or resign due to the condition.
